Chemical Structure
PLX4032 (Vemurafenib), Inhibitor
PLX4032 (Vemurafenib)
Purity
>98%
Synonyms
PLX4032 (Vemurafenib); RG7204; RO5185426; Zelboraf; PLX-4032; inhibitor
Purity/Purification
>98%
Form/Format
Powder
Concentration
0.1 mM: 20.41 mL (1 mg); 102.06 mL (5 mg); 204.12mL (10 mg)
0.5 mM: 4.08 mL (1 mg); 20.41 mL (5 mg); 40.82 mL (10 mg)
1 mM: 2.04 mL (1 mg); 10.21 mL (5 mg); 20.41 mL (10 mg)
5 mM: 0.41 mL (1 mg); 2.04 mL (5 mg); 4.08 mL (10 mg) (varies by lot)
0.5 mM: 4.08 mL (1 mg); 20.41 mL (5 mg); 40.82 mL (10 mg)
1 mM: 2.04 mL (1 mg); 10.21 mL (5 mg); 20.41 mL (10 mg)
5 mM: 0.41 mL (1 mg); 2.04 mL (5 mg); 4.08 mL (10 mg) (varies by lot)
CAS Number
918504-65-1
Formula
C23H18ClF2N3O3S
SMILES
CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F
Actions
Inhibitor
In Vivo Solvent
30% PEG400/0.5% Tween80/5% propylene glycol
Solubility (DMSO)
98 mg/mL (200.03 mM)
Solubility (Ethanol)
<1 mg/mL (<1 mM)
Solubility (in vivo)
5 mg/mL
Solubility (Water)
<1 mg/mL (<1 mM)
Availability
We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
Preparation and Storage
at -20 degree C 3 years Powder
Chemical Structure
Chemical Structure
Related Product Information for PLX4032 (Vemurafenib), inhibitor
PLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
References
Kudo K, .et al. Cell surface CD63 increased by up-regulated polylactosamine modification sensitizes human melanoma cells to the BRAF inhibitor PLX4032, FASEB J, 2018, Dec 3:fj201800664RR PMID: 30508500
Min Ho Choe, .et al. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP, Cell Death Dis, 2018, Jun; 9(6): 640 PMID: 29844307
Jan D??rrie, .et al. BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy, Int J Mol Sci, 2018, Jan; 19(1): 289 PMID: 29346301
Aishwarya Kundu, .et al. Inhibition of Oncogenic BRAF Activity by Indole-3-Carbinol Disrupts Microphthalmia-Associated Transcription Factor Expression and Arrests Melanoma Cell Proliferation, Mol Carcinog, 2017, Jan; 56(1): 49-61. PMID: 26878440
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Toshinori Sueda, .et al. BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells, Sci Rep, 2016, 6: 18949 PMID: 26750638
Yanling Li, .et al. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells, Onco Targets Ther., 2015, 8: 1043-1051 PMID: 25999739
Min Ho Choe, .et al. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP, Cell Death Dis, 2018, Jun; 9(6): 640 PMID: 29844307
Jan D??rrie, .et al. BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy, Int J Mol Sci, 2018, Jan; 19(1): 289 PMID: 29346301
Aishwarya Kundu, .et al. Inhibition of Oncogenic BRAF Activity by Indole-3-Carbinol Disrupts Microphthalmia-Associated Transcription Factor Expression and Arrests Melanoma Cell Proliferation, Mol Carcinog, 2017, Jan; 56(1): 49-61. PMID: 26878440
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Toshinori Sueda, .et al. BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells, Sci Rep, 2016, 6: 18949 PMID: 26750638
Yanling Li, .et al. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells, Onco Targets Ther., 2015, 8: 1043-1051 PMID: 25999739
Similar Products
Product Notes
The PLX4032 (Vemurafenib) (Catalog #AAA386052) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "PLX4032 (Vemurafenib), Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
